{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:56:45Z","timestamp":1790269005512,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-IAHU-03"],"award-info":[{"award-number":["ANR-10-IAHU-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["30\/04\/2020"],"award-info":[{"award-number":["30\/04\/2020"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijantimicag.2020.106202","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T16:58:00Z","timestamp":1602867480000},"page":"106202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Methylene blue inhibits replication of SARS-CoV-2 in vitro"],"prefix":"10.1016","volume":"56","author":[{"given":"Mathieu","family":"Gendrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Andreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Duflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Boxberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Le Bideau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Mosnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Jardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bogreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"La Scola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pradines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106202_bib0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0002","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/trf.13729","article-title":"Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light","volume":"56","author":"Fryk","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0003","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/trf.15332","article-title":"Inactivation of yellow fever virus in plasma after treatment with methylene blue and visible light and in platelet concentrates following treatment with ultraviolet C light","volume":"59","author":"Faddy","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0004","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/jmv.25538","article-title":"Inactivation of Zika virus in plasma and derivatives by four different methods","volume":"91","author":"Wang","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0005","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/trf.14652","article-title":"Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively","volume":"58","author":"Eickmann","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0006","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1099\/jmm.0.001078","article-title":"In vitro activity of methylene blue and eosin methylene blue agar on colistin-resistant A. baumannii: an experimental study","volume":"68","author":"Gazel","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0007","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijantimicag.2016.11.012","article-title":"Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection","volume":"49","author":"Tian","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3759704","article-title":"Nonphotodynamic roles of methylene blue: display of distinct antimycobacterial and anticandidal mode of actions","volume":"2018","author":"Pal","year":"2018","journal-title":"J Pathog"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0009","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jiy386","article-title":"Methylene blue treatment of grafts during cold ischemia time reduces the risk of hepatitis C virus transmission","volume":"218","author":"Helfritz","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0010","first-page":"953","article-title":"Ueber die Wirkung des Methylenblau bei Malaria [About the effect of methylene blue in malaria]","volume":"28","author":"Guttman","year":"1891","journal-title":"Berl Klin Wochenschr"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0011","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1128\/AAC.01466-10","article-title":"In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs","volume":"55","author":"Pascual","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12936-015-0589-3","article-title":"Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013\u20132014 malaria season","volume":"14","author":"Fall","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.03.019","article-title":"Ex vivo activity of Proveblue, a methylene blue, against filed isolates of Plasmodium falciparum in Dakar, Senegal from 2013 to 2015","volume":"50","author":"Fall","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0014","first-page":"2141","article-title":"Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa, 2013\u201318","volume":"75","author":"Gendrot","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0015","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/AAC.00634-13","article-title":"Dose responses of Proveblue methylene blue in an experimental murine cerebral malaria model","volume":"57","author":"Dormoi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0016","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1128\/AAC.02381-12","article-title":"Efficacy of Proveblue (methylene blue) in an experimental cerebral malaria murine model","volume":"57","author":"Dormoi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0017","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1475-2875-12-127","article-title":"Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model","volume":"12","author":"Dormoi","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222993","article-title":"Safety and efficacy of artesunate\u2013amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: a randomized controlled trial","volume":"14","author":"Mendes Jorge","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb Pathog"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0022","article-title":"Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med Dis"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101632","article-title":"Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infection diseases referral hospital in Marseille, France, January 31st to March 1st, 2020: a respiratory virus snapshot","volume":"36","author":"Amrane","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01441-19","article-title":"Pharmacokinetics and ex vivo antimalarial activity of artesunate\u2013amodiaquine plus methylene blue in healthy volunteers","volume":"64","author":"Anh","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0027","series-title":"Clinical pharmacology and biopharmaceutics review(s): application number 204630Orig1s000","year":"2020"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/02841869609101650","article-title":"Targeting disseminated melanoma with radiolabelled methylene blue","volume":"35","author":"Link","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0029","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in the treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammatopharmacology"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jchromb.2017.11.026","article-title":"Simultaneous quantification of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS\/MS: an application for pharmacokinetic studies","volume":"1072","author":"Chhonker","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0031","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkg138","article-title":"Comparative distribution of azithromycin in lung tissue of patient given oral daily doses of 500 and 1000 mg","volume":"51","author":"Danesi","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0032","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jac\/dkn032","article-title":"Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin","volume":"61","author":"Lucchi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0033","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/IDR.S187226","article-title":"In vitro activity and pharmacodynamic\/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections","volume":"12","author":"Davidson","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0034","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/v12050576","article-title":"Antiviral effects of hydroxychloroquine and type I interferon on in vitro fatal feline coronavirus infection","volume":"12","author":"Takano","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0036","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12916-018-1045-3","article-title":"Efficacy and safety of methylene blue in the treatment of malaria: a systemic review","volume":"16","author":"Lu","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ijantimicag.2020.106202_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibits SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:43:43Z","timestamp":1778766223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0924857920304088"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106202","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methylene blue inhibits replication of SARS-CoV-2 in vitro","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106202"}}